AstraZeneca
🇬🇧United Kingdom
- Country
- 🇬🇧United Kingdom
- Ownership
- Public
- Employees
- 89.9K
- Market Cap
- $270.3B
- Website
- http://www.astrazeneca.co.uk
- Introduction
AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.
STYLE - Symbicort Single Inhaler Therapy vs Conventional Therapy in Treatment of Persistent Asthma
Phase 3
Completed
- Conditions
- Asthma
- First Posted Date
- 2005-11-15
- Last Posted Date
- 2011-01-24
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 1000
- Registration Number
- NCT00252824
- Locations
- 🇸🇮
Research Site, Nova Gorica, Slovenia
🇭🇷Researh Site, Dubrovnik, Croatia
Efficacy & Safety of Symbicort® TURBUHALER® 160/4.5 µg Twice Daily & Pulmicort® TURBUHALER® 200 µg Twice Daily + Theolong® Tablet 200 mg Twice Daily in Japanese Asthmatic Patients
Phase 3
Completed
- Conditions
- Asthma
- First Posted Date
- 2005-11-15
- Last Posted Date
- 2011-01-24
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 340
- Registration Number
- NCT00252785
- Locations
- 🇯🇵
Research Site, Toyama, Japan
GALLANT 2 Tesaglitazar vs. Placebo
Phase 3
Terminated
- Conditions
- Type 2 Diabetes
- First Posted Date
- 2005-11-15
- Last Posted Date
- 2009-04-22
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 80
- Registration Number
- NCT00252772
- Locations
- 🇫🇮
Research Site, Ödet, Finland
ZD1839 (Iressa™) and Concurrent Chemo-Radiation in Patients With Locally Advanced Non Small Cell Lung Cancer
Phase 1
Completed
- Conditions
- Non Small Cell Lung Carcinoma
- First Posted Date
- 2005-11-15
- Last Posted Date
- 2007-12-19
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 44
- Registration Number
- NCT00252798
- Locations
- 🇦🇺
Research Site, East Melbourne, Victoria, Australia
Iressa 2nd Line Phase III Study in Japan
Phase 3
Completed
- Conditions
- Non-Small Cell Lung Cancer
- First Posted Date
- 2005-11-15
- Last Posted Date
- 2007-12-18
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 484
- Registration Number
- NCT00252707
- Locations
- 🇯🇵
Research Site, Yamagata, Japan
GALLANT 22 Tesaglitazar vs. Placebo
Phase 3
Terminated
- Conditions
- Type 2 Diabetes
- First Posted Date
- 2005-11-15
- Last Posted Date
- 2008-03-17
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 475
- Registration Number
- NCT00252837
- Locations
- 🇸🇪
Research Site, Åmål, Sweden
DIabetic Retinopathy Candesartan Trials.
- First Posted Date
- 2005-11-15
- Last Posted Date
- 2014-06-03
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 1850
- Registration Number
- NCT00252720
GALLEX 1 - Long Term Extension Study in Patients With Type 2 Diabetes
Phase 3
Terminated
- Conditions
- Type 2 Diabetes
- First Posted Date
- 2005-11-15
- Last Posted Date
- 2008-03-17
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 2000
- Registration Number
- NCT00252876
- Locations
- 🇻🇳
Research Site, Ho Chi Minh, Vietnam
Iressa Case Control Study in Japan
Completed
- Conditions
- Non-small Cell Lung Cancer
- First Posted Date
- 2005-11-15
- Last Posted Date
- 2011-01-28
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 6000
- Registration Number
- NCT00252759
- Locations
- 🇯🇵
Research Site, Toyama, Japan
Esomeprazole (NEXIUM) vs. Surgery
Phase 3
Completed
- Conditions
- Gastroesophageal Reflux
- Interventions
- Procedure: Laparoscopic fundoplication (surgery)
- First Posted Date
- 2005-11-11
- Last Posted Date
- 2012-08-08
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 626
- Registration Number
- NCT00251927
- Locations
- 🇬🇧
Research Site, Salford, United Kingdom
© Copyright 2025. All Rights Reserved by MedPath